Skip to main content
OpenTrials

Clinical trial condition

Breast Neoplasms

Explore clinical trials studying Breast Neoplasms. Study availability and eligibility vary by location and protocol.

685 public trials 115 recruiting studies
Refine in advanced search Browse all conditions

Breast Neoplasms trial results

Recruiting

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

NCT07060807

Conditions
Breast Diseases, Breast Neoplasms, Neoplasms, +3 more
Locations
  • Southern Cancer Center (SCC) ( Site 8000) Daphne, Alabama, United States
  • The University of Arizona Cancer Center - North Campus ( Site 0055) Tucson, Arizona, United States
  • Los Angeles Hematology Oncology Medical Group ( Site 0026) Los Angeles, California, United States
  • Hoag Memorial Hospital Presbyterian ( Site 0025) Newport Beach, California, United States
View all 195 locations
View Trial Details
Recruiting

A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence

NCT06830720

Conditions
Breast Diseases, Breast Neoplasms, Neoplasms, +3 more
Locations
  • Novartis Investigative Site Wiener Neustadt, Lower Austria, Austria
  • Novartis Investigative Site Innsbruck, Tyrol, Austria
  • Novartis Investigative Site Linz, Upper Austria, Austria
  • Novartis Investigative Site Graz, Austria
View all 287 locations
View Trial Details
Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

NCT06312176

Conditions
Breast Diseases, Breast Neoplasms, Neoplasms, +4 more
Locations
  • Ironwood Cancer & Research Centers ( Site 0066) Chandler, Arizona, United States
  • Banner MD Anderson Cancer Center-Oncology ( Site 0004) Gilbert, Arizona, United States
  • Providence Medical Foundation-Oncology ( Site 0020) Fullerton, California, United States
  • Moores Cancer Center ( Site 0059) La Jolla, California, United States
View all 259 locations
View Trial Details
Recruiting

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

NCT06966700

Conditions
Breast Diseases, Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms, +6 more
Locations
  • Banner MD Anderson Cancer Center ( Site 0066) Gilbert, Arizona, United States
  • Mayo Clinic Cancer Center ( Site 0034) Phoenix, Arizona, United States
  • University of Arizona Cancer Center ( Site 0035) Tucson, Arizona, United States
  • Roy and Patricia Disney Family Cancer Center ( Site 0055) Burbank, California, United States
View all 317 locations
View Trial Details
Recruiting

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

NCT07114601

Conditions
Breast Diseases, Breast Neoplasms, Colonic Diseases, +37 more
Locations
  • City of Hope Duarte, California, United States
  • University of California, Los Angeles (UCLA) Santa Monica, California, United States
  • Stanford University Medical Center Stanford, California, United States
  • Biogenix Molecular, LLC Miami, Florida, United States
View all 31 locations
View Trial Details
Recruiting

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

NCT07173751

Conditions
Breast Diseases, Breast Neoplasms, Neoplasms, +3 more
Locations
  • Highlands Oncology Group Springdale, Arkansas, United States
  • University Of California - San Diego Moores Cancer Center La Jolla, California, United States
  • Cedar Sinai - Samuel Oschin Cancer Center Los Angeles, California, United States
  • Stanford University School of Medicine - Stanford Cancer Institute (SCI) - Stanford Women's Cancer Center Palo Alto, California, United States
View all 155 locations
View Trial Details
Recruiting

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

NCT07287098

Conditions
Breast Diseases, Breast Neoplasms, Neoplasms, +3 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Ironwood Cancer & Research Centers Chandler, Arizona, United States
  • USC/Norris Comprehensive Cancer Center Los Angeles, California, United States
  • UCLA Hematology/Oncology - Parkside Santa Monica, California, United States
View all 78 locations
View Trial Details
Recruiting

Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast Cancer

NCT07702708

Conditions
Breast Diseases, Breast Neoplasms, HR+/HER2- Breast Cancer, +4 more
Locations
  • Fujian Cancer Hospital Fuzhou, Fujian, China
  • Fujian Provincial Hospital Fuzhou, Fujian, China
  • The Second Affiliated Hospital of Fujian Medical University Quanzhou, Fujian, China
  • Ningde First Hospital Ningde, China
View Trial Details
Recruiting

PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan

NCT05573893

Conditions
Breast Cancer, Breast Diseases, Breast Neoplasms, +8 more
Locations
  • Research Site Amberg, Germany
  • Research Site Ansbach, Germany
  • Research Site Apolda, Germany
  • Research Site Aschaffenburg, Germany
View all 108 locations
View Trial Details

Related conditions